Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: Modification by triglycerides and cholesteryl ester transfer protein
Objectives: Non-HDL-cholesterol (non-HDL-C) and apolipoprotein (apo) B are proposed as treatment targets. The extent to which statin therapy affects relationships of LDL-C and non-HDL-C with apoB was examined in type 2 diabetes. Methods: Analyses were performed in 217 hypertriglyceridaemic type2 diabetic patients (Diabetes Atorvastatin Lipid Intervention (DALI) cohort). 61patients randomized to placebo, 70 to 10mg atorvastatin daily and 65 - 80mg atorvastin daily completed follow-up. Results: Baseline fasting LDL-C of 2.42 mmol/l and non-HDL-C of 3.69 mmol/l corresponded to the apoB guideline target of 0.90 g/l. During atorvastatin (10 and 80 mg daily), the LDL-C target was achieved most frequently, and lower LDL-C (2.38 and 2.29 mmol/l) and non-HDL-C (3.24 and 3.19 mmol/l) concentrations corresponded to this apoB goal. Decreases in LDL-C during atorvastatin treatment were negatively related (p < 0.001), but decreases in non-HDL-C were positively related to changes in triglycerides (p < 0.001), independently from decreases in apoB (p < 0.001 for all). Decreases in LDL-C and non-HDL-C were positively associated with decreases in cholesteryl ester transfer protein mass (p < 0.001). Conclusions: During atorvastatin lower LDL-C and non-HDL-C levels correspond to the apoB guideline target, which would favour its use as treatment target.
|Keywords||Apolipoprotein B, Atorvastatin, Cholesteryl ester transfer protein, LDL-cholesterol, Non-HDL-cholesterol, Triglycerides|
|Persistent URL||dx.doi.org/10.1517/14728220903023866, hdl.handle.net/1765/25396|
Kappelle, P.J.W.H, Zwang, L, Huisman, M.V, Banga, J.D, Sluiter, W, Dallinga-Thie, G.M, & Dullaart, R.P.F. (2009). Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: Modification by triglycerides and cholesteryl ester transfer protein. Expert Opinion On Therapeutic Targets, 13(7), 743–751. doi:10.1517/14728220903023866